FDA Articulates Design Principles For Pivotal Trials In Final Guidance
This article was originally published in The Gray Sheet
Executive Summary
The agency prefers device pivotal trials to be randomized, double-blinded and controlled, but understands that this is “neither feasible nor practical” for some devices, according to a Nov. 7 final guidance.
You may also be interested in...
Renal Denervation Researcher Argues Sham Control Is Ethically Necessary
The lead investigator on the SYMPLICITY HTN-3 trial says sham-controlled trials are sometimes ethically necessary to prevent patients from undergoing ineffective treatments and warns there may be other medical devices on the market that are not as effective as previously thought.
The Pre-Decisional IDE: FDA’s New Proposal To Help Studies Get Started Right
FDA detailed its proposal for a new “pre-decisional IDE review process” in a revised draft guidance issued June 14. The voluntary process would occur prior to IDE submission and would offer companies comprehensive feedback on where their study plans fall short in gaining IDE approval and in ultimately gaining marketing approval.
FDA Guidance Emphasizes Randomized, Blinded Trials For PMAs
Clinical studies in support of pre-market approval applications should ideally be randomized and blinded, FDA maintains in recent guidance.